WCS is currently focused on preclinical development of the TORVAD. Previous efforts have thoroughly evaluated the technology and revealed multiple advantages with the potential to greatly impact patient outcomes. Anticipated clinical impact include reduced incidence of strokes, bleeding, and thrombus due to the unique hematological and physiological aspects of the TORVAD.
WCS was formed in 2005 as a spin-off of a research collaboration between cardiologist Dr. Richard W. Smalling at UTHealth (Houston) and Dr. Raul G. Longoria, a professor of Mechanical Engineering at the University of Texas at Austin. This research and the company formation was initially funded exclusively through private investment. Since 2013, continued research and development has been supported by three SBIR grants awarded by the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH).
One SBIR grant is targeting design and development of a pediatric TORVAD, which is scheduled for in vitro and in vivo testing in the spring of 2017.
The most recent NIH SBIR grant is a three year Phase IIB award made in May 2016. This grant will support development of the adult TORVAD toward gaining an Investigative Device Exemption (IDE) to initiate first-in-man clinical studies. This grant requires yearly matching funds from a strategic partner or partners, and WCS is currently in negotiations with potential candidates that can fill this role. Please contact company CEO Dr. Richard Smalling directly if you are interested in discussing partnering with WCS (Email: email@example.com).